PMID- 22211798
OWN - NLM
STAT- MEDLINE
DCOM- 20121009
LR  - 20220114
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 53
IP  - 6
DP  - 2012 Jun
TI  - Different immunoprofiles in patients with chronic myeloid leukemia treated with 
      imatinib, nilotinib or dasatinib.
PG  - 1084-9
LID - 10.3109/10428194.2011.647017 [doi]
AB  - Immunomodulation induced by dasatinib is reportedly related to better prognosis 
      in chronic myeloid leukemia (CML). However, the underlying mechanism has not yet 
      been fully elucidated. The immunoprofiles of 63 patients in the chronic phase of 
      CML were evaluated during treatment with a tyrosine kinase inhibitor (imatinib, n 
      = 36; nilotinib, n = 9; dasatinib, n = 18). The numbers of CD56 + CD57 + and CD3 
      + CD57 + cells increased significantly in the dasatinib group. The numbers of 
      regulatory T-cells were comparable among the three groups. Dasatinib markedly 
      enhanced natural killer (NK)-cell reactivity. Only one patient treated with 
      dasatinib showed a slight cytomegalovirus (CMV) reactivation. In contrast, 
      nilotinib suppressed NK-cell reactivity. Plasma levels of interleukin-8 (IL-8), 
      interferon-gamma inducible protein-10 (IP-10) and monocyte chemoattractant protein-1 
      (MCP-1) were significantly elevated in all three groups, and plasma levels of 
      granulocyte macrophage-colony stimulating factor (GM-CSF) were significantly 
      elevated in the imatinib and dasatinib groups. Our results suggest the presence 
      of a mechanism for dasatinib-associated immunomodulatory effects that is distinct 
      from CMV reactivation and a decreased number of regulatory T-cells.
FAU - Hayashi, Yoshiki
AU  - Hayashi Y
AD  - Graduate School of Medicine, Osaka City University, Osaka, Japan.
FAU - Nakamae, Hirohisa
AU  - Nakamae H
FAU - Katayama, Takako
AU  - Katayama T
FAU - Nakane, Takahiko
AU  - Nakane T
FAU - Koh, Hideo
AU  - Koh H
FAU - Nakamae, Mika
AU  - Nakamae M
FAU - Hirose, Asao
AU  - Hirose A
FAU - Hagihara, Kiyoyuki
AU  - Hagihara K
FAU - Terada, Yoshiki
AU  - Terada Y
FAU - Nakao, Yoshitaka
AU  - Nakao Y
FAU - Hino, Masayuki
AU  - Hino M
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120120
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzamides)
RN  - 0 (Chemokines)
RN  - 0 (Cytokines)
RN  - 0 (Piperazines)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 0 (Thiazoles)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - F41401512X (nilotinib)
RN  - RBZ1571X5H (Dasatinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/therapeutic use
MH  - Benzamides
MH  - Chemokines/blood/metabolism
MH  - Cytokines/blood/metabolism
MH  - Dasatinib
MH  - Female
MH  - Humans
MH  - Imatinib Mesylate
MH  - Immunophenotyping
MH  - K562 Cells
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood/*drug therapy/*immunology
MH  - Lymphocyte Subsets/drug effects/immunology/metabolism/physiology
MH  - Male
MH  - Middle Aged
MH  - Piperazines/*therapeutic use
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Pyrimidines/*therapeutic use
MH  - Thiazoles/*therapeutic use
MH  - Young Adult
EDAT- 2012/01/04 06:00
MHDA- 2012/10/10 06:00
CRDT- 2012/01/04 06:00
PHST- 2012/01/04 06:00 [entrez]
PHST- 2012/01/04 06:00 [pubmed]
PHST- 2012/10/10 06:00 [medline]
AID - 10.3109/10428194.2011.647017 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2012 Jun;53(6):1084-9. doi: 10.3109/10428194.2011.647017. Epub 
      2012 Jan 20.